Ipamorelin
IP10 · 10mg · 2026-08-29 · N/A
COA PDF ↗
IP2Images are illustrative. Actual specifications are as selected and confirmed in writing.
Growth Hormone & IGF-1
GH secretion, bone growth and body composition
Ipamorelin specifications and reference prices. Select a specification to add it to your cart.
For laboratory research only. Not for human or veterinary use.
IP10 · 10mg · 2026-08-29 · N/A
COA PDF ↗| SKU | Specification / pack | Reference price (USD) |
|---|---|---|
| IP2 | 2mg/vial x 10vials | US$47.06 |
| IP5 | 5mg/vial x 10vials | US$100 |
| IP10 | 10mg/vial x 10vials | US$154.55 |
Temporarily sold-out specifications can still be added to an inquiry to ask about restocking. An inquiry is not an order or an agreed price.
Explore Growth Hormone & IGF-1 ↗ · View all products
This page organizes directly related information on GH secretion, bone growth, and body composition of Ipamorelin. First, look at the research questions and findings, then verify the population or species, study preparations, and scope of interpretation.
Ipamorelin shows antagonistic effects on the decline of certain muscle strength and bone formation. Other studies report: increased bone mineral content and bone volume, providing evidence for GH-related bone metabolism.[1] ↗ [2] ↗
Ipamorelin shows antagonistic effects on the decline of certain muscle strength and bone formation.[1] ↗
Adult female rats; glucocorticoid-related catabolic model, 3 months
Specific hormone injury model; cannot infer muscle gain or height increase in healthy adults.
Growth Hormone & IGF Research: official journal of the Growth Hormone Research Society and the International IGF Research Society · Volume/Issue Year 2001
First published 2001-10-01 · PMID 11735244
DOI 10.1054/ghir.2001.0239
Bone mineral content and bone volume increase, providing evidence for GH-related bone metabolism.[2] ↗
Adult female rats; 12-week Ipamorelin or GHRP-6 intervention
Weight-adjusted total bone mineral content ratio and volumetric bone density did not improve; not confirmed as human osteoporosis.
The Journal of Endocrinology · Volume, Issue, Year 2000
First published 2000-06-01 · PMID 10828840
DOI 10.1677/joe.0.1650569
GH release was observed at all study doses, providing human physiological evidence for its GH secretion mechanism.[3] ↗
Healthy male volunteers; Ipamorelin dose-escalation infusion pharmacokinetic/pharmacodynamic study
Only indicates short-term hormone response; does not prove muscle growth, height increase, or anti-aging; 1999 basic research.
Pharmaceutical Research · Volume and Issue Year 1999
First published 1999-09-01 · PMID 10496658
DOI 10.1023/a:1018955126402
Longitudinal bone growth rate increased in a dose-dependent manner.[4] ↗
Adult female rats; 15 days
1999; cannot be promoted as adult height increase or human muscle growth.
Growth Hormone & IGF Research: official journal of the Growth Hormone Research Society and the International IGF Research Society · Volume/Issue Year 1999
First published 1999-04-01 · PMID 10373343
DOI 10.1054/ghir.1999.9998
Currently, 4 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Compare study populations, findings and scope.
Ipamorelin shows antagonistic effects on the decline of certain muscle strength and bone formation. Other studies report: increased bone mineral content and bone volume, providing evidence for GH-related bone metabolism.[1] ↗ [2] ↗
Not possible. Short-term human trials record GH release, and animal studies observe bone growth and metabolism; these endpoints differ from adult height increase, muscle strength, or long-term body composition benefits.[3] ↗ [4] ↗ [2] ↗
Adult female rats; glucocorticoid-related catabolic model, 3 months; adult female rats; 12-week Ipamorelin or GHRP-6 intervention; healthy male volunteers; Ipamorelin dose-escalation infusion pharmacokinetic/pharmacodynamic study. Specific hormone injury model; cannot infer muscle gain or height increase in healthy adults.[1] ↗ [2] ↗ [3] ↗
VENTRO PEPTIDES & BIOTECH · RESEARCH PRODUCT RETAIL
Compare specifications, reference prices and COA reports. Add products to your cart to request a quote.
01 / CATALOG
Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
10mg/vial x 10vials
US$90.91Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
20mg/vial x 10vials
US$160.61Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
10mg/vial x 10vials
US$109.09Images are illustrative. Actual specifications are as selected and confirmed in writing.
Repair & Recovery Research
10mg/vial x 10vials
US$133.33Images are illustrative. Actual specifications are as selected and confirmed in writing.
Longevity & Mitochondrial Research
20mg/vial x 10vials
US$257.58Images are illustrative. Actual specifications are as selected and confirmed in writing.
GLP-1 & Metabolic Research
10mg*10vials
US$164.71Images are illustrative. Actual specifications are as selected and confirmed in writing.
Growth Hormone & IGF-1
1mg/vial x 10vials
US$505.8802 / DISCOVER
03 / ABOUT VENTRO
Ventro supports research product retail purchases with clear pack specifications, available quality documents, and responsive international support.
04 / QUALITY SYSTEM
Browse the available COA reports by product. Confirm documentation for your order with our team.
RESEARCH PRODUCT INQUIRY
Tell us the product, specification, and expected quantity. Our team will respond with pricing and available documents.